AAPS PharmSciTech

, 10:1357 | Cite as

Design and In Vitro Evaluation of Novel Sustained-Release Double-Layer Tablets of Lornoxicam: Utility of Cyclodextrin and Xanthan Gum Combination

  • Yassin El-Said Hamza
  • Mona Hassan AburahmaEmail author
Research Article


The objective of the present study was to develop new directly compressed, double-layer tablets (DLTs) of lornoxicam, a highly potent nonsteroidal anti-inflammatory drug with short half-life, that are characterized by initial burst drug release in the stomach and comply with the release requirements of sustained-release products. Each of the proposed DLTs is composed of a fast-release layer and a sustained-release layer, anticipating rapid drug release that starts in the stomach to rapidly alleviate the symptoms and continues in the intestine to maintain protracted analgesic effect. An amorphous, freeze-dried inclusion complex of lornoxicam with hydroxypropyl-β-cyclodextrin, present in 1:2 (drug/cyclodextrin) molar ratio, was employed in the fast-release layer to enhance the dissolution of lornoxicam in the stomach and assure rapid onset of its analgesic effect. Xanthan gum (XG), a hydrophilic matrix-forming agent, was integrated in the sustained-release layer to provide appropriate sustainment of drug release. The weight ratios between the sustained-release layer and fast-release layer present in DLTs were adjusted to reach optimal formulations. DLTs composed of sustained-release layer (40% XG) to fast-release layer in 2:1 weight ratio and those composed of sustained-release layer (50% XG) to fast-release layer in 1:1 weight ratio showed the desired release profile. The drug contained in the fast-release layer showed an initial burst drug release of more than 30% of its drug content during the first 30 min of the release study followed by gradual release of the drug for a period of 8 h.

Key words

cyclodextrins double-layer tablets lornoxicam sustained release xanthan gum 


  1. 1.
    Merck & Co. Inc. The Merck index. 13th ed. Whitehouse Station: Merck & Co. Inc.; 2001.Google Scholar
  2. 2.
    Homdrum EM, Likar R, Nell G. Xefo® Rapid: a novel effective tool for pain treatment. Eur Surg. 2006;38:342–52.CrossRefGoogle Scholar
  3. 3.
    Kidd B, Frenzel W. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol. 1996;23:1605–11.PubMedGoogle Scholar
  4. 4.
    Balfour JA, Fitton A, Barradell LB. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of and inflammatory conditions. Drugs. 1996;51:639–57.CrossRefPubMedGoogle Scholar
  5. 5.
    Skjodt NM, Davies NM. Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin Pharmacokinet. 1998;34:421–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Lin SZ, Wouessidjewe D, Poelman MC, Duchene D. In vivo evaluation of indomethacin/cyclodextrin complexes. Gastrointesinal tolerance and dermal anti-inflammatory activity. Int J Pharm. 1994;106:63–7.CrossRefGoogle Scholar
  7. 7.
    Patra CN, Kumar AB, Pandit HK, Singh SP. Design and evaluation of sustained release bilayer tablets of propranolol hydrochloride. Acta Pharm. 2007;57:479–89.CrossRefPubMedGoogle Scholar
  8. 8.
    Uekama K, Matsubara K, Abe K, Horiuchi Y, Hirayamma F, Suzuki N. Design and in vitro evaluation of slow-release dosage form of piretanide: utility of beta-cyclodextrin: cellulose derivative combination as a modified-release drug carrier. J Pharm Sci. 1990;79:244–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Wang Z, Horikawa T, Hirayama F, Uekama K. Design and in-vitro evaluation of a modified-release oral dosage form of nifedipine by hybridization of hydroxypropyl-beta-cyclodextrin and hydroxypropylcellulose. J Pharm Pharmacol. 1993;45:942–6.PubMedGoogle Scholar
  10. 10.
    Kumar A, Agarwal SP, Khanna R. Modified release bi-layered tablet of melatonin using beta-cyclodextrin. Pharmazie. 2003;58:642–4.PubMedGoogle Scholar
  11. 11.
    Yan G, Li H, Zhang R, Ding D. Preparation and evaluation of a sustained-release formulation of nifedipine HPMC tablets. Drug Dev Ind Pharm. 2000;26:681–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Fassihi RA, Ritschel WA. Multiple-layer, direct-compression, controlled-release system: in vitro and in vivo evaluation. J Pharm Sci. 1993;82:750–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Lopes CM, Sousa Lobo JM, Pinto JF, Costa PC. Compressed matrix core tablet as a quick/slow dual-component delivery system containing ibuprofen. AAPS PharmSciTech. 2007;8(3):E76.CrossRefPubMedGoogle Scholar
  14. 14.
    Maggi L, Machiste EO, Torre ML, Conte U. Formulation of biphasic release tablets containing slightly soluble drugs. Eur J Pharm Biopharm. 1999;48:37–42.CrossRefPubMedGoogle Scholar
  15. 15.
    Badr-Eldin SM, Elkheshen SA, Ghorab MM. Inclusion complexes of tadalafil with natural and chemically modified β-cyclodextrins. I: preparation and in-vitro evaluation. Eur J Pharm Biopharm. 2008;70:819–27.CrossRefPubMedGoogle Scholar
  16. 16.
    Klein S, Wempe MF, Zoeller T, Buchanan NL, Ramsey MG, Edgar KJ, et al. Improving glyburide solubility and dissolution by complexation with hydroxybutenyl-β-cyclodextrin. J Pharm Pharmacol. 2009;61:23–30.CrossRefPubMedGoogle Scholar
  17. 17.
    Sathigari S, Chadha G, Lee YH, Wright N, Parsons DL, Rangari VK, et al. Physicochemical characterization of efavirenz–cyclodextrin inclusion complexes. AAPS PharmSciTech. 2009;10:81–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Jun SW, Kim MS, Kim JS, Park HJ, Lee S, Woo JS, et al. Preparation and characterization of simvastatin/hydroxypropyl-β-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm. 2007;66:413–21.CrossRefPubMedGoogle Scholar
  19. 19.
    Manosroi J, Apriyani MG, Foe K, Manosroi A. Enhancement of the release of azaleic acid through the synthetic membranes by inclusion complex formation with hydroxypropyl-β-cyclodextrin. Int J Pharm. 2005;293:235–40.CrossRefPubMedGoogle Scholar
  20. 20.
    Cirri M, Rangoni C, Maestrelli F, Corti G, Mura P. Development of fast-dissolving tablets of flurbiprofen–cyclodextrin complexes. Drug Dev Ind Pharm. 2005;31:697–707.CrossRefPubMedGoogle Scholar
  21. 21.
    Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev. 1998;98:2045–76.CrossRefPubMedGoogle Scholar
  22. 22.
    Mundargi RC, Patil SA, Aminabhavi TM. Evaluation of acrylamide-grafted-xanthan gum copolymer matrix tablets for oral controlled delivery of antihypertensive drugs. Carbohydr Polymer. 2007;69:130–41.CrossRefGoogle Scholar
  23. 23.
    Gohel MC, Parikh RK, Nagori SA, Jena D. Fabrication of modified release tablet formulation of metoprolol succinate using hydroxypropyl methylcellulose and xanthan gum. AAPS PharmSciTech. 2009;10:62–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Yeole PG, Galgatte UC, Babla IB, Nakhat PD. Design and evaluation of xanthan gum-based sustained release matrix tablets of diclofenac sodium. Indian J Pharm Sci. 2006;68:185–9.CrossRefGoogle Scholar
  25. 25.
    Higuchi T, Connors KA. Phase solubility techniques. Adv Anal Chem Instr. 1965;4:117–212.Google Scholar
  26. 26.
    Loftsson T, Masson M, Sigurjonsdottir JF. Methods to enhance the complexation efficiency of cyclodextrin. STP Pharma Sci. 1999;9:237–42.Google Scholar
  27. 27.
    Baboota S, Agarwal SP. Preparation and characterisation of meloxicam hydroxypropyl β-cyclodextrin inclusion complex. J Incl Phenom Macrocycl Chem. 2005;51:219–24.CrossRefGoogle Scholar
  28. 28.
    Khan KA, Rhodes CT. Effect of compaction pressure on the dissolution efficiency of direct compression systems. Pharm Acta Helv. 1972;47:594–607.PubMedGoogle Scholar
  29. 29.
    Lopes CM, Sousa Lobo JM, Pinto JF, Costa P. Compressed mini-tablets as a biphasic delivery system. Int J Pharm. 2006;323:93–100.CrossRefPubMedGoogle Scholar
  30. 30.
    Al-Taani BM, Tashtoush BM. Effect of microenvironment pH of swellable and erodable buffered matrices on the release characteristics of diclofenac sodium. AAPS PharmSciTech. 2003;4(3):E43.CrossRefPubMedGoogle Scholar
  31. 31.
    Corti G, Cirri M, Maestrelli F, Mennini N, Mura P. Sustained-release matrix tablets of metformin hydrochloride in combination with triacetyl-beta-cyclodextrin. Eur J Pharm Biopharm. 2008;68:303–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Liew CV, Chan LW, Ching AL, Heng PW. Evaluation of sodium alginate as drug release modifier in matrix tablets. Int J Pharm. 2006;309:25–37.CrossRefPubMedGoogle Scholar
  33. 33.
    British Pharmacopoeia Commission. The British Pharmacopoeia. London: British Pharmacopoeia Commission, HMSO; 2007. (electronic version).Google Scholar
  34. 34.
    Arima H, Yunomae K, Miyake K, Irie T, Hirayama F, Uekama K. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J Pharm Sci. 2001;90:690–701.CrossRefPubMedGoogle Scholar
  35. 35.
    Loftsson T, Mȃsson M, Brewster ME. Self-association of cyclodextrins and cyclodextrin complexes. J Pharm Sci. 2004;93:1091–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Rajendrakumar K, Madhusudan S, Pralhad T. Cyclodextrin complexes of valdecoxib: properties and anti-inflammatory activity in rat. Eur J Pharm Biopharm. 2005;60:39–46.CrossRefPubMedGoogle Scholar
  37. 37.
    Fernandes CM, Teresa VM, Veiga FJ. Physicochemical characterization and in vitro dissolution behavior of nicardipine–cyclodextrins inclusion compounds. Eur J Pharm Sci. 2002;15:79–88.CrossRefPubMedGoogle Scholar
  38. 38.
    Mura P, Faucci MT, Bettinetti GP. The influence of the polyvinylpyrrolidone on naproxen complexation with hydroxypropyl β-cyclodextrin. Eur J Pharm Sci. 2001;13:187–94.CrossRefPubMedGoogle Scholar
  39. 39.
    Suryanarayanan R, Rastogi S. X-ray powder diffractometry. In: Swarbrick J, editor. Encyclopedia of pharmaceutical technology, vol. 6. New York: Marcel Dekker; 2007. p. 4103–17.Google Scholar
  40. 40.
    Moyano JR, Ginés JM, Arias MJ, Rabasco AM. Study of the dissolution characteristics of oxazepam via complexation with β-cyclodextrin. Int J Pharm. 1995;114:95–102.CrossRefGoogle Scholar
  41. 41.
    Ribeiro L, Ferreira DC, Veiga FJ. In vitro controlled release of vinpocetine–cyclodextrin–tartaric acid multicomponent complexes from HPMC swellable tablets. J Control Release. 2005;103:325–39.CrossRefPubMedGoogle Scholar
  42. 42.
    Davis SS, Hardy JG, Taylor MJ, Whalley DR, Wilson CG. A comparative study of the gastrointestinal transit of a pellet and tablet formulation. Int J Pharm. 1984;21:167–77.CrossRefGoogle Scholar
  43. 43.
    Alderman DA. A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms. Int J Pharm Technol Prod Manuf. 1984;5:1–9.Google Scholar
  44. 44.
    El-Gazayerly ON. Release of pentoxifylline from xanthan gum matrix tablets. Drug Dev Ind Pharm. 2003;29:241–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Cohen JL, Hubert BB, Rhodes CT. The development of USP dissolution and drug release standards. Pharm Res. 1990;7:983–7.CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2009

Authors and Affiliations

  1. 1.Department of Pharmaceutics and Industrial Pharmacy, Faculty of PharmacyCairo UniversityCairoEgypt

Personalised recommendations